Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China
· Delayed Price · Currency is CNY 57.21
-0.74 (-1.28%)
Mar 9, 2026, 3:00 PM CST
SHA:688513 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | - | 238.23 | 226.57 | 246.52 | 232.43 | Upgrade
|
| Depreciation & Amortization | - | 81.37 | 73.23 | 58.35 | 32.6 | Upgrade
|
| Other Amortization | - | 3.14 | 1.49 | 1.34 | 1.19 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 0 | -0.13 | -0.26 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 0.11 | 0.11 | 0.07 | 0.1 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -24.76 | -25.48 | -27.84 | -42.04 | Upgrade
|
| Provision & Write-off of Bad Debts | - | 3.03 | -0.36 | 1.42 | -2.25 | Upgrade
|
| Other Operating Activities | - | 9.34 | 6.12 | 4.81 | 2.24 | Upgrade
|
| Change in Accounts Receivable | - | -112.44 | -75.72 | -51.53 | -181.32 | Upgrade
|
| Change in Inventory | - | -34.8 | -22.74 | -39.5 | -21.55 | Upgrade
|
| Change in Accounts Payable | - | 82.73 | 90.2 | -45.57 | 129.14 | Upgrade
|
| Change in Other Net Operating Assets | - | 19.98 | 1.23 | -0.06 | 0.39 | Upgrade
|
| Operating Cash Flow | - | 263.24 | 275.25 | 151.94 | 147.6 | Upgrade
|
| Operating Cash Flow Growth | - | -4.36% | 81.15% | 2.95% | -5.70% | Upgrade
|
| Capital Expenditures | - | -117.42 | -175.26 | -339.33 | -270.19 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.49 | 0.26 | 0.33 | - | Upgrade
|
| Investment in Securities | - | 313.56 | -234.53 | -81.41 | 160.61 | Upgrade
|
| Other Investing Activities | - | - | -0.65 | 14.71 | -1.01 | Upgrade
|
| Investing Cash Flow | - | 196.63 | -410.17 | -405.7 | -110.59 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | 30 | Upgrade
|
| Long-Term Debt Issued | - | 150 | 235 | 100 | - | Upgrade
|
| Total Debt Issued | - | 150 | 235 | 100 | 30 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | -50 | Upgrade
|
| Long-Term Debt Repaid | - | -253.92 | -91.48 | -50 | - | Upgrade
|
| Total Debt Repaid | - | -253.92 | -91.48 | -50 | -50 | Upgrade
|
| Net Debt Issued (Repaid) | - | -103.92 | 143.52 | 50 | -20 | Upgrade
|
| Issuance of Common Stock | - | 34.76 | - | - | - | Upgrade
|
| Common Dividends Paid | - | -74.11 | -71.08 | -96.05 | -36.4 | Upgrade
|
| Other Financing Activities | - | -118.99 | 8.22 | 85.74 | - | Upgrade
|
| Financing Cash Flow | - | -262.27 | 80.67 | 39.7 | -56.4 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 0.03 | -0.07 | 0.02 | -0.01 | Upgrade
|
| Net Cash Flow | - | 197.64 | -54.32 | -214.04 | -19.39 | Upgrade
|
| Free Cash Flow | - | 145.82 | 99.99 | -187.38 | -122.59 | Upgrade
|
| Free Cash Flow Growth | - | 45.83% | - | - | - | Upgrade
|
| Free Cash Flow Margin | - | 10.80% | 8.95% | -16.01% | -11.98% | Upgrade
|
| Free Cash Flow Per Share | - | 0.83 | 0.56 | -1.06 | -0.70 | Upgrade
|
| Cash Income Tax Paid | - | 147.05 | 91.73 | 108.05 | 118.32 | Upgrade
|
| Levered Free Cash Flow | - | -13.92 | 47.75 | -258.5 | -90.64 | Upgrade
|
| Unlevered Free Cash Flow | - | -11.62 | 49.89 | -256.87 | -90.41 | Upgrade
|
| Change in Working Capital | - | -47.22 | -6.3 | -132.46 | -76.67 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.